Genetic Disruption of PPAR(delta) Decreases Tumorigenicity of Human Colon Cancer Cells

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are involved in many normal and disease related processes, such as lipid metabolism and cancer. Specifically, isotype PPAR�as been proposed as a downstream target in the adenomatous polyposis coli (APC)/�atenin pathway in colorectal cancer. When JHU researchers inoculated the PPAR�nockout of HCT116 cells as xenografts into nude mice, the cells demonstrated a decreased ability to form tumors. Details are described in the paper by Park et al., 2001 Description (Set) Proposed Use (Set) The invention suggests that inhibition of PPAR?ould be used as a therapeutic tool in the treatment of colon cancer. PPAR?s an excellent target for pharmaceutical development as it is a receptor and ligands could be designed as antagonists

Inventor(s): Vogelstein, Bert

Type of Offer: Licensing



« More Medical Patents

---